secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001213900-25-052377
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX posts updated corporate presentation; no material new disclosures
-----------------------------------------------------------------------

- Posted updated slide deck in Investors section of website on June 9, 2025.
- Presentation titled 'Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance'.
- No specific financial data, guidance changes, or clinical milestones disclosed in the filing.
- Filed under Regulation FD; company undertakes no obligation to update the materials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/0001213900-25-052377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/ea0245109-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-052377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer